iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.4050
-0.0050 (-1.22%)
Aug 28, 2026, 5:07 PM SGT
iX Biopharma Financials Overview
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Revenue Revenue Growth | 6.85 | 6.85 | 7.77 | 5.96 | 5.91 | 14.39 |
Revenue Growth | -11.77% | -11.77% | 30.34% | 0.78% | -58.91% | 724.64% |
Gross Profit Gross Profit Growth | 2.43 | 2.43 | 2.04 | 1.05 | 2.32 | 12.29 |
Operating Income Operating Income Growth | -9.56 | -9.56 | -6.29 | -7.5 | -9.54 | 0.5 |
Net Income Net Income Growth | -7.99 | -7.99 | -10.14 | -10.79 | -9.62 | -4.6 |
Earnings Per Share EPS Growth | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Specialty Pharmaceuticals Specialty Pharmaceuticals Growth | 5.63 | 5.63 | 7.07 | 5.65 | 5.35 | 13.92 |
Nutraceutical Nutraceutical Growth | 1.69 | 1.69 | 1.11 | 0.51 | 0.75 | 0.62 |
Inter-Segment Sales Inter-Segment Sales Growth | -0.47 | -0.47 | -0.42 | -0.2 | -0.19 | -0.15 |
Total Total Growth | 6.85 | 6.85 | 7.77 | 5.96 | 5.91 | 14.39 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Investments Cash & Investments Growth | 14.74 | 14.74 | 0.94 | 1.84 | 6.53 | 13.59 |
Total Debt Total Debt Growth | 5.8 | 5.8 | 5.9 | 5.2 | 4.34 | 4.41 |
Net Cash (Debt) Net Cash Growth | 8.93 | 8.93 | -4.97 | -3.36 | 2.2 | 9.18 |
Net Cash Growth | - | - | - | - | -76.08% | 363.97% |
Net Cash Per Share Net Cash Per Share Growth | 0.01 | 0.01 | -0.01 | -0.00 | 0.00 | 0.01 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -7.51 | -7.51 | -3.76 | -6.55 | -7.66 | 3.12 |
Capital Expenditures CapEx Growth | -0.12 | -0.12 | -0.2 | -0.27 | -0.7 | -0.2 |
Free Cash Flow Free Cash Flow Growth | -7.62 | -7.62 | -3.96 | -6.83 | -8.36 | 2.92 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Gross Margin | 35.52% | 35.52% | 26.27% | 17.59% | 39.24% | 85.41% |
Operating Margin | -139.52% | -139.52% | -80.92% | -125.78% | -161.41% | 3.48% |
Pretax Margin | -116.50% | -116.50% | -130.55% | -167.56% | -164.15% | -28.49% |
Profit Margin | -116.64% | -116.64% | -130.56% | -181.14% | -162.61% | -31.95% |
FCF Margin | -111.21% | -111.21% | -50.97% | -114.57% | -141.30% | 20.31% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
P/FCF Ratio | - | - | - | - | - | 41.89 |
PS Ratio | 64.37 | 56.89 | 1.83 | 3.74 | 11.79 | 8.51 |